BUND FINANCE › Stocks › TAK
Takeda Pharmaceutical Company Limited (TAK)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +8.93% above its 50-day average.
- It is +19.35% above its 200-day average (long-term uptrend).
- It sits at 92% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | JPY 3.57T | JPY 4.03T | JPY 4.26T | JPY 4.58T | JPY 4.78T |
| Net income | JPY 230.1B | JPY 317.0B | JPY 144.1B | JPY 107.9B | JPY 203.3B |
| EPS (diluted) | 72.94 | 100.97 | 45.58 | 33.62 | 63.91 |
| Gross margin | 69.0% | 69.1% | 66.4% | 65.5% | 51.1% |
| Operating margin | 12.9% | 12.2% | 5.0% | 7.5% | 12.0% |
| Net margin | 6.5% | 7.9% | 3.4% | 2.4% | 4.3% |
| Free cash flow | JPY 937.1B | JPY 343.5B | JPY 235.6B | JPY 677.6B | JPY 626.8B |
| Total debt | JPY 4.35T | JPY 4.38T | JPY 4.84T | JPY 4.52T | JPY 4.90T |
| Cash | JPY 849.7B | JPY 533.5B | JPY 457.8B | JPY 385.1B | JPY 597.6B |
Compound annual growth: revenue 7.6% · net income -3.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | — | 40.3x | 27.1x |
| EV / EBITDA | — | 8.8x | 16.5x |
| Operating margin | 13.7% | — | 3.6% |
| Net margin | 8.2% | — | -0.0% |
| Debt / equity | 1.06 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreemen…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice